Newsome SD, et al. A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis. Abstract 60. ECTRIMS 11-13 sept 2019, Stockholm, Zweden.
Onderliggende oorzaken TIA en minor stroke beïnvloeden risico ernstig vasculair event
dec 2023 | Atherosclerose, Neuro-vasculair